ERBB2 and breast carcinoma: Denkert’s recent study evaluating a cohort of breast cancer patients from four prospective clinical trials indicated that HER2-low disease was a favorable prognostic factor with superior DFS and OS compared to HER2-zero tumors only in the HR− subgroup [7].